References
Julia A Belk, Winnie Yao, Nghi Ly, Katherine A Freitas, Yan-Ting Chen, Quanming Shi, Alfredo M Valencia, Eric Shifrut, Nupura Kale, Kathryn E Yost, Connor V Duffy, Bence Daniel, Madeline A Hwee, Zhuang Miao, Alan Ashworth, Crystal L Mackall, Alexander Marson, Julia Carnevale, Santosh A Vardhana, and Ansuman T Satpathy. Genome-wide crispr screens of t cell exhaustion identify chromatin remodeling factors that limit t cell persistence. Cancer Cell, 40:768–786.e7, 2022. URL: https://www.sciencedirect.com/science/article/pii/S1535610822002318, doi:https://doi.org/10.1016/j.ccell.2022.06.001.
Xiuqiong Chen, Zhaona Li, Xinyue Wang, Jing Zhou, Qianhui Wei, Kaidi Chen, and Richeng Jiang. Investigation and verification of gimap6 as a robust biomarker for prognosis and tumor immunity in lung adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 149:11041–11055, 2023. URL: https://doi.org/10.1007/s00432-023-04980-z, doi:10.1007/s00432-023-04980-z.
Geyang Dai, Yue Sun, Rui Wei, and Ling Xi. Small leucine-rich proteoglycan podnl1 identified as a potential tumor matrix-mediated biomarker for prognosis and immunotherapy in a pan-cancer setting. Current Issues in Molecular Biology, 45:6116–6139, 2023. URL: https://www.mdpi.com/1467-3045/45/7/386, doi:10.3390/cimb45070386.
Gavin I Ellis, Lianteng Zhi, Ravi Akundi, Hansruedi Büeler, and Francesc Marti. Mitochondrial and cytosolic roles of pink1 shape induced regulatory t-cell development and function. European Journal of Immunology, 43:3355–3360, 12 2013. URL: https://doi.org/10.1002/eji.201343571, doi:https://doi.org/10.1002/eji.201343571.
Block Jana, Rashkova Christina, Castanon Irinka, Zoghi Samaneh, Platon Jessica, Ardy Rico C, Fujiwara Mitsuhiro, Chaves Beatriz, Schoppmeyer Rouven, van der Made Caspar I, Jimenez Heredia Raul, Harms Frederike L, Alavi Samin, Alsina Laia, Sanchez Moreno Paula, Ávila Polo Rainiero, Cabrera-Pérez Rocío, Kostel Bal Sevgi, Pfajfer Laurène, Ransmayr Bernhard, Mautner Anna-Katharina, Kondo Ryohei, Tinnacher Anna, Caldera Michael, Schuster Michael, Domínguez Conde Cecilia, Platzer René, Salzer Elisabeth, Boyer Thomas, Brunner Han G, Nooitgedagt-Frons Judith E, Iglesias Estíbaliz, Deyà-Martinez Angela, Camacho-Lovillo Marisol, Menche Jörg, Bock Christoph, Huppa Johannes B, Pickl Winfried F, Distel Martin, Yoder Jeffrey A, Traver David, Engelhardt Karin R, Linden Tobias, Kager Leo, Hannich J Thomas, Hoischen Alexander, Hambleton Sophie, Illsinger Sabine, Da Costa Lydie, Kutsche Kerstin, Chavoshzadeh Zahra, van Buul Jaap D, Antón Jordi, Calzada-Hernández Joan, Neth Olaf, Viaud Julien, Nishikimi Akihiko, Dupré Loïc, and Boztug Kaan. Systemic inflammation and normocytic anemia in dock11 deficiency. New England Journal of Medicine, 389:527–539, 8 2023. URL: https://doi.org/10.1056/NEJMoa2210054, doi:10.1056/NEJMoa2210054.
María Jiménez-Fernández, Cristina Rodríguez-Sinovas, Laia Cañes, Carme Ballester-Servera, Alicia Vara, Silvia Requena, Hortensia de la Fuente, José Martínez-González, and Francisco Sánchez-Madrid. Cd69-oxldl ligand engagement induces programmed cell death 1 (pd-1) expression in human cd4 + t lymphocytes. Cellular and Molecular Life Sciences, 79:468, 2022. URL: https://doi.org/10.1007/s00018-022-04481-1, doi:10.1007/s00018-022-04481-1.
Weiqiang Ju, Shiqing Chen, Guoqiang Wang, Shangli Cai, Jianping Xiong, and Xiaojun Xiang. Association between mdm2/mdm4 amplification and pd-1/pd-l1 inhibitors-related hyperprogressive disease: a pan-cancer analysis. Journal of Clinical Oncology, 37:2557, 7 2025. URL: https://doi.org/10.1200/JCO.2019.37.15_suppl.2557, doi:10.1200/JCO.2019.37.15_suppl.2557.
Marlene Langenbach, Sophie Giesler, Stefan Richtsfeld, Sara Costa-Pereira, Lukas Rindlisbacher, Tobias Wertheimer, Lukas M Braun, Geoffroy Andrieux, Sandra Duquesne, Dietmar Pfeifer, Nadine M Woessner, Hans D Menssen, Sanaz Taromi, Justus Duyster, Melanie Börries, Tilman Brummer, Bruce R Blazar, Susana Minguet, Patrick Turko, Mitchell P Levesque, Burkhard Becher, and Robert Zeiser. Mdm2 inhibition enhances immune checkpoint inhibitor efficacy by increasing il15 and mhc class ii production. Molecular Cancer Research, 21:849–864, 8 2023. URL: https://doi.org/10.1158/1541-7786.MCR-22-0898, doi:10.1158/1541-7786.MCR-22-0898.
Claire Lhuillier, Nils-Petter Rudqvist, Takahiro Yamazaki, Tuo Zhang, Maud Charpentier, Lorenzo Galluzzi, Noah Dephoure, Cristina C Clement, Laura Santambrogio, Xi Kathy Zhou, Silvia C Formenti, and Sandra Demaria. Radiotherapy-exposed cd8+ and cd4+ neoantigens enhance tumor control. The Journal of Clinical Investigation, 3 2021. URL: https://doi.org/10.1172/JCI138740, doi:10.1172/JCI138740.
Haiyang Li, Na Zheng, Anning Guo, Weiwei Tang, Muxin Li, Yuanyuan Cao, Xinhua Ma, Hongyong Cao, Yong Ma, Hanjin Wang, and Shuli Zhao. Fstl3 promotes tumor immune evasion and attenuates response to anti-pd1 therapy by stabilizing c-myc in colorectal cancer. Cell Death & Disease, 15:107, 2024. URL: https://doi.org/10.1038/s41419-024-06469-0, doi:10.1038/s41419-024-06469-0.
Lei Li, Mingyang Li, Jianyi Zheng, Zeyu Li, and Xiaonan Chen. Knocking down nsun5 inhibits the development of clear cell renal cell carcinoma by inhibiting the p53 pathway. Aging, 15:4757–4773, 1 2023. URL: https://doi.org/10.18632/aging.204761, doi:10.18632/aging.204761.
Erika L Pearce, Maya C Poffenberger, Chih-Hao Chang, and Russell G Jones. Fueling immunity: insights into metabolism and lymphocyte function. Science, 342:1242454, 10 2013. URL: https://doi.org/10.1126/science.1242454, doi:10.1126/science.1242454.
Shuai Ping, Siyuan Wang, Yingsong Zhao, Jinbing He, Guanglei Li, Dinglin Li, Zhuo Wei, and Jianghai Chen. Identification and validation of a ferroptosis-related gene signature for predicting survival in skin cutaneous melanoma. Cancer Medicine, 11:3529–3541, 9 2022. URL: https://doi.org/10.1002/cam4.4706, doi:https://doi.org/10.1002/cam4.4706.
Jing Song, Yongyao Tang, Xiaoyong Luo, Xinpeng Shi, Fangzhou Song, and Longke Ran. Pan-cancer analysis reveals the signature of tmc family of genes as a promising biomarker for prognosis and immunotherapeutic response. Frontiers in Immunology, 11 2021. doi:10.3389/fimmu.2021.715508.
Shicheng Su, Jianyou Liao, Jiang Liu, Di Huang, Chonghua He, Fei Chen, LinBing Yang, Wei Wu, Jianing Chen, Ling Lin, Yunjie Zeng, Nengtai Ouyang, Xiuying Cui, Herui Yao, Fengxi Su, Jian-dong Huang, Judy Lieberman, Qiang Liu, and Erwei Song. Blocking the recruitment of naive cd4+ t cells reverses immunosuppression in breast cancer. Cell Research, 27:461–482, 2017. URL: https://doi.org/10.1038/cr.2017.34, doi:10.1038/cr.2017.34.
Yuma Sugiyama, Mitsuhiro Fujiwara, Akihiko Sakamoto, Hiromichi Tsushima, Akihiko Nishikimi, and Mitsuo Maruyama. The immunosenescence-related factor dock11 is involved in secondary immune responses of b cells. Immunity & Ageing, 19:2, 2022. URL: https://doi.org/10.1186/s12979-021-00259-4, doi:10.1186/s12979-021-00259-4.
Aiting Wang, Mengdi Yang, Rui Liang, Fangming Zhu, Fuxiang Zhu, Xinnan Liu, Yichao Han, Ruirong Lin, Xiaoxia Wang, Dan Li, Hecheng Li, Xiaojun Yuan, Hui Zhao, and Bin Li. Mouse double minute 2 homolog-mediated ubiquitination facilitates forkhead box p3 stability and positively modulates human regulatory t cell function. Frontiers in Immunology, 6 2020. doi:10.3389/fimmu.2020.01087.
Jiangna Yan, Jinglin Zhu, Xiaolan Li, Ruijie Yang, Wei Xiao, Chao Huang, and Chunli Zheng. Blocking ltb4 signaling-mediated tams recruitment by rhizoma coptidis sensitizes lung cancer to immunotherapy. Phytomedicine, 119:154968, 2023. URL: https://www.sciencedirect.com/science/article/pii/S094471132300329X, doi:https://doi.org/10.1016/j.phymed.2023.154968.
Shuai Yang, Xinyao Qiu, Yingcheng Yang, Jing Wu, Shan Wang, Bo Zheng, Jianmin Wu, Tao Zhou, Yangqianwen Zhang, Mixue Bai, Shuowu Liu, Zihan Zhao, Yani Zhang, Yixian Wang, Jinxia Bao, Mengye Wu, Dongdong Xue, Meiyu Bao, Ji Hu, Siyun Shen, Hongyang Wang, and Lei Chen. Lta4h improves the tumor microenvironment and prevents hcc progression via targeting the hnrnpa1/ltbp1/tgf-β axis. Cell Reports Medicine, 6:102000, 2025. URL: https://www.sciencedirect.com/science/article/pii/S2666379125000734, doi:https://doi.org/10.1016/j.xcrm.2025.102000.